Sheikh F Ahmad Selected Research

Imiquimod (Aldara)

1/2022	Lck signaling inhibition causes improvement in clinical features of psoriatic inflammation through reduction in inflammatory cytokines in CD4+ T cells in imiquimod mouse model.
12/2020	Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice.
6/2020	Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
3/2020	Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
3/2019	Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis.
1/2018	Systemic inflammation in asocial BTBR T+ tf/J mice predisposes them to increased psoriatic inflammation.
5/2017	Psoriasis-like inflammation leads to renal dysfunction via upregulation of NADPH oxidases and inducible nitric oxide synthase.
1/2017	Psoriatic inflammation enhances allergic airway inflammation through IL-23/STAT3 signaling in a murine model.
1/2017	IL-17A causes depression-like symptoms via NFκB and p38MAPK signaling pathways in mice: Implications for psoriasis associated depression.
1/2017	GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sheikh F Ahmad Research Topics

Disease

38	Inflammation (Inflammations) 09/2022 - 05/2015
32	Autistic Disorder (Autism) 05/2022 - 01/2017
10	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2020 - 09/2015
10	Asthma (Bronchial Asthma) 10/2019 - 05/2015
7	Neuroinflammatory Diseases 01/2020 - 10/2017
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/2022 - 06/2021
4	Acute Kidney Injury (Acute Renal Failure) 10/2021 - 05/2018
4	Experimental Arthritis 03/2021 - 12/2019
4	Neoplasms (Cancer) 01/2019 - 03/2016
4	Nervous System Diseases (Neurological Disorders) 01/2019 - 10/2017
3	Pneumonia (Pneumonitis) 09/2022 - 11/2015
3	Autism Spectrum Disorder 01/2022 - 06/2020
3	Sepsis (Septicemia) 01/2021 - 05/2018
3	Acute Lung Injury 06/2020 - 06/2017
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 01/2016
3	Rheumatoid Arthritis 01/2020 - 12/2019
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 01/2017
2	Otitis 01/2022 - 01/2017
2	Arthritis (Polyarthritis) 03/2021 - 06/2007
2	Carcinogenesis 01/2020 - 01/2019
2	Hepatocellular Carcinoma (Hepatoma) 12/2019 - 05/2016
2	Cardiotoxicity 11/2017 - 03/2016
1	Demyelinating Diseases (Demyelinating Disease) 01/2022
1	Memory Disorders (Memory Loss) 01/2022
1	Communicable Diseases (Infectious Diseases) 03/2021
1	Multiple Sclerosis 01/2021
1	Encephalomyelitis (Myeloencephalitis) 01/2021
1	Chromosomal Instability (Chromosome Stability) 01/2021

Drug/Important Bio-Agent (IBA)

20	CytokinesIBA 01/2022 - 09/2015
14	Interleukin-17 (Interleukin 17)IBA 01/2022 - 05/2016
13	AntioxidantsIBA 02/2021 - 05/2015
12	Imiquimod (Aldara)FDA LinkGeneric 01/2022 - 09/2015
11	Transcription Factors (Transcription Factor)IBA 01/2022 - 09/2015
10	3-nitrotyrosineIBA 10/2021 - 07/2015
10	Peroxidase (Myeloperoxidase)IBA 06/2020 - 09/2015
8	Proteins (Proteins, Gene)FDA Link 09/2022 - 07/2015
8	Lipid PeroxidesIBA 02/2021 - 05/2015
8	NADPH Oxidases (NAD(P)H oxidase)IBA 02/2021 - 04/2016
8	Oxidants (Oxidizing Agents)IBA 02/2021 - 05/2015
6	Chemokine ReceptorsIBA 01/2022 - 02/2018
5	Phosphotransferases (Kinase)IBA 01/2022 - 10/2019
5	AllergensIBA 10/2019 - 04/2016
5	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2018 - 01/2017
4	phthalic acid (phthalate)IBA 05/2022 - 12/2020
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 01/2018
4	CreatinineIBA 10/2021 - 05/2017
4	Diethylhexyl Phthalate (DEHP)IBA 02/2021 - 01/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2019
4	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 06/2020 - 07/2015
3	Interleukin-10 (Interleukin 10)IBA 10/2021 - 06/2020
3	Interleukin-9 (Interleukin 9)IBA 03/2021 - 10/2017
3	EnzymesIBA 02/2021 - 04/2016
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 10/2019
3	PlasticizersIBA 01/2021 - 01/2018
3	N- (1- (3- (4- ethoxyphenyl)- 4- oxo- 3,4- dihydropyrido(2,3- d)pyrimidin- 2- yl)ethyl)- N- pyridin- 3- ylmethyl- 2- (4- trifluoromethoxyphenyl)acetamideIBA 07/2020 - 12/2019
3	ibrutinibIBA 06/2020 - 10/2019
3	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2019 - 01/2018
3	ChemokinesIBA 05/2019 - 05/2016
3	Syk KinaseIBA 03/2019 - 03/2019
3	Urea (Carbamide)FDA LinkGeneric 03/2019 - 05/2017
3	NitrogenIBA 03/2019 - 05/2017
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 01/2017
3	AnthracyclinesIBA 11/2017 - 01/2016
3	Dexrazoxane (Zinecard)FDA LinkGeneric 11/2017 - 01/2016
2	lead nitrateIBA 09/2022 - 09/2022
2	Pharmaceutical PreparationsIBA 01/2022 - 08/2020
2	Therapeutic UsesIBA 02/2021 - 10/2019
2	5-aminoisoquinolinoneIBA 02/2021 - 01/2020
2	Environmental Pollutants (Pollutants, Environmental)IBA 02/2021 - 01/2021
2	GlucocorticoidsIBA 07/2020 - 11/2015
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 07/2020 - 11/2015
2	Toll-Like Receptor 4IBA 07/2020 - 03/2017
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2020 - 01/2017
2	AG 127 (AG 126)IBA 01/2020 - 01/2018
2	TyrphostinsIBA 01/2020 - 01/2018
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2018
2	Dexamethasone (Maxidex)FDA LinkGeneric 10/2019 - 01/2018
2	sulforaphaneIBA 07/2019 - 01/2019
2	Peptide Hydrolases (Proteases)FDA Link 05/2019 - 07/2015
2	Acetates (Acetic Acid Esters)FDA Link 05/2018 - 01/2017
2	Interleukin-17 ReceptorsIBA 01/2018 - 01/2017
2	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2017 - 07/2015
2	Dual OxidasesIBA 01/2017 - 07/2015
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2016 - 07/2015
1	NF-kappa B (NF-kB)IBA 09/2022
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 09/2022
1	AcidsIBA 06/2022
1	methylmercuric chlorideIBA 01/2022
1	N- (3- propylcarbamoyloxirane- 2- carbonyl)- isoleucyl- prolineIBA 01/2022
1	UCB 35625IBA 01/2022
1	1-methyl-1H-indole-2-carboxylic acid (4- (1- (4- (4- acetylpiperazin- 1- yl)cyclohexyl)- 4- amino- 1H- pyrazolo(3,4- d)pyrimidin- 3- yl)- 2- methoxyphenyl)amideIBA 01/2022
1	Cathepsin BIBA 01/2022
1	SB-332235IBA 01/2022
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	statticIBA 06/2021
1	Chemokine CCL5IBA 03/2021
1	CC ChemokinesIBA 03/2021
1	Maraviroc FDA Link 03/2021
1	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 01/2021

Therapy/Procedure

10	Therapeutics 01/2022 - 09/2015